 BERLIN and SAN DIEGO, Sept. 09, 2021 GLOBE NEWSWIRE -- atai Life Sciences Nasdaq: ATAI atai, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutics, Inc. Introspect, today announced a usability study of Introspects digital therapeutic DTx app technology in support of standard of care ketamine therapy for patients with treatment resistant depression TRD in collaboration with Kadima Neuropsychiatry. TRD impacts 100 million people globally, close to a third of the 300 million diagnosed with depression, many of whom are geographically restricted in their ability to access in-person psychological care. 